Hepatitis Market Analysis and Reports | UK Conference Series

Market Analysis - Hepatitis 2017

Hepatitis is an inflammatory condition of the liver caused by the hepatitis virus. The most observed types of this disease are hepatitis A, hepatitis B and hepatitis C. Globally, 350 million people are chronically infected with any one form of hepatitis and around 500,000 people die every year according to World Health Organization.

Hepatitis A is a simpler form of which does not lead to chronic infections. Patients suffering from hepatitis A recover within two months as this form is less complicated and can be prevented with vaccination.

Although hepatitis B can be prevented by vaccination, once infected, a person can develop lifelong chronic infection resulting into severe liver damage. More than 2 billion people of the global population are infected with hepatitis B. Hepatitis B patients are vulnerable to further complications related to the liver, such as: hepatocellular carcinoma (liver cancer), liver failure, and liver cirrhosis.

Hepatitis C is most dangerous of among all the types of hepatitis as 80% of the hepatitis C infected patients get chronically infected. Around 150 million people are infected with hepatitis C worldwide and 350,000 people die every year. It has a cure rate of less than 80%, which drops below 60% in some regions of the world. The low cure rate is supplemented in most regions by a lack of an effective vaccine against hepatitis C. Recent estimates find that about 215,000 people in the UK are chronically infected with hepatitis C.

The global demand for Hepatitis C drug Market is expected to reach 27.63 billion USD in 2021 at a CAGR of 17% between 2016 and 2021, which was 11.81 billion USD in 2015. Key applications of hepatitis C drug market are hospitals, private labs, public health labs, blood banks and physician offices. Hepatitis C drug market can be driven by the elements like prevalence of the infection, new productive treatments, rising government subsidizing and relatively lesser time of treatment. Hepatitis C market can be influenced by treatment costs, lack of awareness and information about HCV disease.

In the United States, 20 percent to 30 percent of people living with HIV are coinfected with HCV. Hepatitis C is common among people living with HIV. This means that about 225,000 to 330,000 people in the United States are living with both viruses. The majority of people living with hepatitis C do not know they have it. The most common route of transmission in the UK is using non-sterile needles and other equipment for injecting drugs. 90 percent of people who got HIV from injecting drugs are also infected with HCV. This is because both viruses can be spread easily through blood and blood products.

HBV therapeutics market grow from $2.4 billion in 2014 to $3.0 billion in 2024 at a compound annual growth rate (CAGR) of 2.4%.

Siemens AG, MedMira Inc., Inovio Pharmaceuticals, Inc. and Abbott Laboratories are lead players involved in the development of hepatitis diagnostics.

Gilead Sciences launched couple of drugs Harvoni ((ledipasvir/sofosbuvir) and Sovaldi (sofosbuvir) in the market for Hepatitis C which captured maximum market share and has cure rate of more than 95%. In the coming years, ongoing research on hepatitis C drug development in pharmaceutical industry is expected to increase the market growth. Due to prevalence of the disease, interest for Hepatitis C medication is expanding in Africa, Middle East, Asia Pacific and Latin America. 

Liver Associations

  • European Association for the Study of the Liver (EASL)
  • Euroliver Foundation
  • British Association for the Study of the Liver (BASL)
  • British Liver Trust - National charity for adult liver disease
  • American Association for the Study of Liver Diseases (AASLD)
  • American Hepato-Pancreato-Biliary Association (AHPBA)
  •  American Liver Foundation (ALF)           
  • Texas Society for Gastroenterology and Endoscopy
  • International Hepato Pancreato Biliary Association (IHPBA)
  • Canadian Association for the Study of the Liver (CASL) - Canada (CA)
  • Canadian Liver Foundation (CLF) - Canada (CA)
  • Latin American Association for the Study of the Liver (ALEH)
  • International Association for the Study of the Liver (IASL)
  • Childhood Liver Tumour Study Group (SIOPEL) 
  • Liver Kids Australia
  • Children's Liver Disease Foundation (CLDF)
  • Hepatitis B Foundation
  • Hepatitis Foundation International          
  • Asian Pacific Association for the Study of the Liver (APASL)
  • Hong Kong Liver Foundation - Hong Kong (HK), China
  • Immunization Action Coalition
  • International Liver Transplantation Society (ILTS)
  • Swiss Association for the Study of the Liver (SASL) - Switzerland (CH)

Medical Colleges in UK

  • Imperial College London
  • University College London
  • King's College London
  • Queen Mary University of London
  • St. George’s, University of London
  • The University of Buckingham
  • University of Oxford
  • University of Cambridge
  • University of Southampton
  • Hull York Medical School
  • Cardiff University School of Medicine
  • Keele University School of Medicine
  • University of Glasgow
  • Warwick Medical School
  • Brighton and Sussex Medical School
  • Norwich Medical School
  • University of Aberdeen
  • Leicester Medical School
  • Swansea University Medical School
  • The University of Sheffield
  • University of St Andrews School of Medicine
  • University of Birmingham Medical School
  • Leeds School of Medicine
  • University of Edinburgh Medical School
  • Lancaster Medical School

Drug Approvals and Launches:

  • In 2012, the European Commission approved the use of Viread for the treatment of chronic HBV infection. Viread is also approved for the treatment of HIV infection.
  • Patent expiration for Viread in USA is 2018 and 2017 in EU.
  • In December 2013, FDA approved Sovaldi for the treatment of HCV as a component of a combination antiviral treatment regimen. In January 2014, European Commission approved Sovaldi for the treatment of HCV. Patent expiration for Sovaldi in USA is 2029 and 2028 in EU.
  • In October 2014, Gilead received FDA approval and in November 2014 Gilead received European Commission approval of Harvoni, the first once-daily single tablet regimen for the treatment of HCV genotype 1 infected patients. Patent expiration for Harvoni in USA and EU is 2030.
  • In December 2014,VIEKIRA PAK was approved by the FDA.
  • In July 2015, the FDA approved AbbVie's Technivie for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States.
  • In January 2016, the FDA approved Zepatier for the treatment of adult patients with chronic HCV GT1 or GT4 infection, with or without ribavirin. Patent expiration for Intron A and Zepatier in USA is 2020 and 2031 respectively.
  • Novira Therapeutics is developing a lead core inhibitor candidate, NVR 3-778. NVR 3-778 is a potent inhibitor of HBV replication both in cell culture models and a humanized liver mouse model of CHB. It disrupts the HBV lifecycle by inducing the assembly of defective capsids. NVR 3-778 is currently under Phase 1 clinical trial in New Zealand.
  • Other Novira therapeutics drug such as “2nd Generation Core Inhibitor” and “cccDNA” inhibitor are under discovery stage of development.

FDA approved Drugs for HBV treatment:

  • Baraclude (entecavir)
  • Epivir HBV (lamivudine)
  • Viread (tenofovir disoproxil fumarate)
  • Hepsera (adefovir dipivoxil)
  • Pegasys (pegylated interferon)
  • Intron A (interferon alpha-2b)
  • Tyzeka (telbivudine)

FDA approved Drugs for HCV treatment:

  • CoPegus (ribavirin)
  • Daklinza (daclatasvir)
  • Epclusa (sofosbuvir, velpatasvir)
  • Harvoni (ledipasvir/sofosbuvir)
  • Incivek (telaprevir)
  • Infergen (interferon aphacon-1)
  • Olysio (simeprevir)
  • Pegintron (pegylated interferon alpha-2b)
  • Rebetol (ribavirin)
  • Roferon (interferon alpha-2a)
  • Sovaldi (sofosbuvir)
  • Technivie (ombitasvir, paritaprevir and ritonavir)
  • Victrelis (boceprevir)
  • Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets)
  • Zepatier (elbasvir, grazoprevir)

Companies manufacturing Liver equipment’s

  • Echosens
  • KMC Systems
  • Argon Medical devices Inc
  • Humedics

FDA approved drugs in 2016 for Hepatology

  • Defitelio
  • Ocaliva

Name

Manufacturer

2013

2014

2015

Baraclude

Bristol-Myers Squibb

$ 1.52 Millions

$ 14.4 Millions

$ 1.31 Millions

 Viread

Gilead

$ 959 Millions

$ 1.05 Millions

$1.10 Millions

Harvoni

Gilead

 -

$ 2.12 Millions

$ 13.86 Millions

Incivek

Vertex Pharmaceuticals

$ 466.36 Millions

$ 24.07 Millions

$ 17.98 Million

Olysio

Janssen Therapeutics

$ 23 Millions

$ 2.30 Millions

$ 621 Millions

Pegintron

Merck

$ 496 Millions

$ 381 Millions

$ 182 Millions

Sovaldi

Gilead

$ 139 Millions

$ 10.28 Millions

$ 5.27 Millions

Victrelis

Merck

$ 428 Millions

$ 153 Million

$ 18 Million

Viekira Pak

AbbVie Inc

 -

$ 48 Millions

$ 1.63 Million

 

List of Manufacturing Companies:

  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Gilead Sciences
  • Schering
  • Roche
  • Novartis
  • Vertex Pharmaceuticals
  • Three Rivers Pharma
  • Janssen Pharmaceuticals
  • AbbVie Inc.
  • Merck & Co.
  • Merck Sharp Dohme

Drugs in Clinical Development:

  • Tenofovir Alafenamide Fumarate (Gilead): TAF is a nucleotide reverse transcriptase inhibitor currently under Phase III stage of development for the treatment of Chronic HBV infection.
  • GS-9620 (Gilead): GS-9620 is a TLR-7 agonist indicated for Chronic HBV infection is under Phase II stage of development.
  • GS-4997 (Gilead): GS-4997 is an ASK-1 inhibitor indicated for NASH and alcoholic hepatitis is currently under Phase II stage of development.
  • GS-9674 (Gilead): GS-9674 is a FXR agonist indicated for NASH, Primary Sclerosing Cholangitis and Primary biliary cirrhosis is currently under Phase II stage of development.
  • GS-0976 (Gilead): GS-0976 is an ACC Inhibitor indicated for NASH is currently under Phase II stage of development.
  • 3228836 (Glaxosmithkline): 3228836 is a HBV antisense oligonucleotide indicated for hepatitis B is currently under Phase I stage of clinical development.
  • 3389404 (Glaxosmithkline): 3389404 is a HBV LICA antisense oligonucleotide indicated for hepatitis B is currently under Phase I stage of clinical development.
  • 2878175 (Glaxosmithkline): 2878175 is a non-structural protein 5B (NS5B) polymerase inhibitor indicated for hepatitis C is currently under Phase I stage of clinical development.
  • ARO-HBV (Arrowhead): ARO-HBV is being developed for patients with chronic hepatitis B infection. It is currently under preclinical stage of development.
  • ARO-AAT (Arrowhead): ARO-AAT is being developed to treat the liver disease associated with alpha-1 antitrypsin deficiency. It is currently under preclinical stage of development.
  • Myrcludex-B (MYR GmbH): Myrcludex B, a first-in-class drug for treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV) infection completed Phase 2a clinical trial in chronic hepatitis B and a pilot trial in HDV infection is ongoing.

For more details contact Program Director

E: hepatitis@conferenceseries.net; hepatitis@gastroconferences.com

T: 650-268-9744 | M: 702-508-5202

LinkedIn: https://www.linkedin.com/in/joseph-raven-219270aa

Conference Series invites you to attend 5th World Congress on Hepatitis and Liver diseases (Hepatitis 2017) to be held in London, UK during August 10-12, 2017. The conference highlights the theme “Early diagnosis, treatment of viral hepatitis and optimizing therapy costs”.

Hepatitis 2017 is a best platform with its well organized scientific program to the audience which includes symposiums, workshops, keynote lectures, plenary talks, panel discussions and poster sessions on latest research and technological developments in the arena as well as therapeutic aspects. The conference invites Hepatologists, Gastroenterologists, Internists, Physicians, Microbiologists, Virologists, Pathologists, Oncologists, Surgeons, Toxicologists, Researchers, Students, Business delegates and Young researchers across the globe.

Scope of the Conference

Hepatitis 2017 provides a great platform by gathering eminent professors, Researchers, Students and delegates to exchange new ideas.  The conference will cover a wide range of topics and allow participants to discuss about the management of liver diseases. Hepatitis 2017 conference consists of keynote and plenary lectures, special sessions (Workshop and Symposium), Young Researcher Forum and Poster presentations. Best poster presenters will be judged and awarded during the conference. To encourage broad participation from all over the world Conference Series LLC is offering reduced registration fee for students.